Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

Antibodies, Monoclonal, Humanized Arthritis, Psoriatic / drug therapy Humans Outcome Assessment, Health Care Quality of Life Severity of Illness Index Treatment Outcome
BIOLOGIC THERAPY INFLAMMATION INTERLEUKINS PSORIATIC ARTHRITIS

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
01 06 2020
Historique:
accepted: 27 09 2019
pubmed: 17 10 2019
medline: 1 9 2021
entrez: 17 10 2019
Statut: ppublish

Résumé

To compare the efficacy of secukinumab with that of placebo across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT) individual psoriatic arthritis (PsA) core domains using pooled data from 4 phase III PsA studies and 1 phase III ankylosing spondylitis (AS) study. Data were pooled from 2049 patients with PsA participating in 4 on-label phase III PsA studies (FUTURE 2-5), and the efficacy of each GRAPPA-OMERACT PsA core domain (musculoskeletal disease activity, skin disease activity, pain, patient's global assessment, physical function, health-related quality of life, fatigue, and systemic inflammation) was assessed using multiple measures and definitions specific to each domain. The MEASURE 2 study, a phase III clinical trial in patients with AS, was used to assess improvement in spine symptoms at Week 16. Treatment with secukinumab demonstrated robust and consistent efficacy across all GRAPPA-OMERACT PsA core domains, with secukinumab 300 mg showing the greatest response rates across most PsA core domains compared with placebo at Week 16. Notably, among patients treated with secukinumab 300 mg, 34.3% and 19.5% achieved complete resolution of swollen and tender joint counts, respectively; 53.2% and 61.5% achieved complete resolution of enthesitis and dactylitis, respectively; and 33.2% achieved 100% improvement in Psoriasis Area and Severity Index (all p < 0.05 vs placebo); similar improvements were shown for all other core domains. This analysis suggests that secukinumab can benefit people with PsA across the clinical phenotypic spectrum commonly encountered in this disease.

Identifiants

DOI: 10.3899/jrheum.190507 PMID: 31615919
pubmed: 31615919
pii: jrheum.190507
doi: 10.3899/jrheum.190507
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
secukinumab DLG4EML025

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

854-864

Subventions

Organisme : NIAMS NIH HHS
ID : P30 AR070254
Pays : United States

Auteurs

Ana-Maria Orbai (AM)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA. aorbai1@jhmi.edu.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis. aorbai1@jhmi.edu.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington. aorbai1@jhmi.edu.
ORCID: 0000-0001-8644-8567

Iain B McInnes (IB)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Laura C Coates (LC)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

M Elaine Husni (ME)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Dafna D Gladman (DD)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.
ORCID: 0000-0002-9074-0592

Laure Gossec (L)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Luminita Pricop (L)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Olivier Chambenoit (O)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Xiangyi Meng (X)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Philip J Mease (PJ)

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
A.M. Orbai has received grant support and consulting fees from Novartis. I.B. McInnes has received consulting fees from Novartis. L.C. Coates has received grant support, consulting fees, and speakers bureau fees from Novartis. D.D. Gladman has received grant support and consulting fees from Novartis. L. Gossec has received consulting fees from Novartis. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P.J. Mease has received research grants, consulting fees, and speakers bureau fees from Novartis.
A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; I.B. McInnes, MD, PhD, University of Glasgow; L.C. Coates, MBChB, PhD, University of Oxford; M.E. Husni, MD, MPH, Cleveland Clinic; D.D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP; L. Pricop, MD, Novartis Pharmaceuticals Corp.; O. Chambenoit, PhD, Novartis Pharmaceuticals Corp.; X. Meng, PhD, Novartis Pharmaceuticals Corp.; P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Effect of Secukinumab on the Different...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses papulosquameuses › Psoriasis › Arthrite psoriasique › Effect of Secukinumab on the Different...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effect of Secukinumab on the Different...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Effect of Secukinumab on the Different...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Effect of Secukinumab on the Different...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Effect of Secukinumab on the Different...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Effect of Secukinumab on the Different...